X4 Pharmaceuticals granted new employees options to purchase an aggregate of 80,000 common shares under its 2019 Inducement Equity Incentive Plan. The options have a ten-year term and an exercise price of $2.90 per share, equal to X4’s closing stock price on September 30, 2026. Twenty-five percent of the shares will vest after 12 months, with the remainder vesting monthly over the following 36 months, subject to continued employment. The awards were approved by X4’s Compensation Committee and issued as employment inducements under Nasdaq Listing Rule 5635(c)(4). X4 develops therapies for rare hematology diseases and markets mavorixafor as XOLREMDI for WHIM syndrome in the U.S. and EU. Its global pivotal Phase 3 4WARD trial is evaluating mavorixafor in chronic neutropenic disorders, and the U.S. Food and Drug Administration has granted the treatment Fast Track designation for chronic neutropenia.